‌

US Patent 11492407 Bispecific checkpoint inhibitor antibodies

Patent 11492407 was granted and assigned to Xencor on November, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Patent Applicant

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Umesh S. Muchhal0

Alex Nisthal0

Christine Bonzon0

Gregory Moore0

John Desjarlais0

Matthew Bernett0

Michael Hedvat0

Date of Patent

November 8, 2022

0

Patent Application Number

164353750

Date Filed

June 7, 2019

0

Patent Citations

US Patent 10981992 Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors

0

US Patent 11312770 Bispecific and monospecific antibodies using novel anti-PD-1 sequences

US Patent 11066483 Cytotoxicity-inducing therapeutic agent

0

US Patent 10227410 Heterodimeric antibodies that bind CD3 and PSMA

US Patent 10428155 Trispecific antibodies

US Patent 10526417 Heterodimeric antibodies that bind CD3 and CD38

US Patent 10787518 Bispecific checkpoint inhibitor antibodies

US Patent 10793632 Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors

0

Patent Primary Examiner

0

CPC Code

0

0

0

0

The present invention is directed to heterodimeric anti-LAG-3×anti-CTLA-4. Also provided are nucleic acid compositions that encode the antibodies, expression vector compositions that include the nucleic acids, and host cells that include the expression vector compositions.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11492407 Bispecific checkpoint inhibitor antibodies

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.